Unknown PHASE2 INTERVENTIONAL 2-arm NCT00914251

Vascular Effects of Hesperidin in Metabolic Syndrome

Positive Vascular Effect of Hesperidin in Subjects Affected by Metabolic Syndrome

Sponsor: University of Rome Tor Vergata

Conditions Endothelial Dysfunction Metabolic Syndrome

Updated 5 times since 2017 Last updated: Jun 16, 2009 Started: Nov 30, 2008 Primary completion: Mar 31, 2009 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Endothelial Dysfunction and Metabolic Syndrome, this trial is ongoing. The trial is conducted by University of Rome Tor Vergata and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rome Tor Vergata

Data source: University of Rome Tor Vergata

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy